尹照萍

【摘要】 目的：探討氨溴索治疗慢阻肺合并肺部感染患者的效果及对气道阻力的影响。方法：选取本院2019年1月-2021年1月收治的慢阻肺合并肺部感染患者100例为研究对象，采用随机数字表法将其分为对照组（给予常规治疗）和研究组（在对照组基础上给予氨溴索治疗），每组50例。比较两组患者的临床综合疗效，治疗前后的气道阻力指标、气道重塑指标，临床症状消失时间。结果：治疗15、30 d后，研究组患者的总有效率均高于对照组，差异均有统计学意义（P<0.05）;治疗15、30 d后，研究组的气道阻力指标、气道重塑指标均优于对照组，差异均有统计学意义（P<0.05）;研究组患者的咳嗽、气促、胸闷和肺部啰音消失时间均短于对照组，差异均有统计学意义（P<0.05）。结论：采用氨溴索治疗慢阻肺合并肺部感染患者的临床效果显著，能够显著改善患者气道阻力、气道重塑，促进患者尽快恢复，是临床治疗慢阻肺合并肺部感染的可靠方法之一。

【关键词】 氨溴索 慢阻肺 肺部感染 气道阻力

Effect of Ambroxol on Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Infection and Its Effect on Airway Resistance/YIN Zhaoping. //Medical Innovation of China， 2021， 18（32）： 0-030

[Abstract] Objective： To investigate the effect of Ambroxol on chronic obstructive pulmonary disease complicated with pulmonary infection and its effect on airway resistance. Method： From January 2019 to January 2021， 100 patients with chronic obstructive pulmonary disease complicated with pulmonary infection treated in our hospital were selected as the research objects. They were randomly divided into control group （routine treatment） and study group （Ambroxol treatment on the basis of control group）， with 50 cases in each group. The clinical comprehensive efficacy， airway resistance index， airway remodeling index and the disappearance time of clinical symptoms were compared between the two groups. Result： After 15 and 30 d of treatment， the total effective rates of the study group were higher than those of the control group， the differences were statistically significant （P<0.05）; after 15 and 30 d of treatment， the indexes of airway resistance and airway remodeling in the study group were better than those in the control group， the differences were statistically significant （P<0.05）; the disappearance time of cough， shortness of breath， chest tightness and pulmonary rales in the study group were shorter than those in the control group， the differences were statistically significant （P<0.05）. Conclusion： Ambroxol has a significant clinical effect in the treatment of COPD patients with pulmonary infection， it can significantly improve the airway resistance and airway remodeling， and promote the recovery of patients as soon as possible， it is one of the reliable methods for the clinical treatment of COPD patients with pulmonary infection.

[Key words] Ambroxol COPD Pulmonary infection Airway resistance

First-author’s address： Panjin Liaoyou Baoshihua Hospital， Panjin 124010， China

doi：10.3969/j.issn.1674-4985.2021.32.007

慢性阻塞性肺疾病是呼吸系统疾病之一，临床特点表现为不完全可逆的气流受限，并且患者通常会因出现全身反应而威胁生命健康[1-2]。慢性阻塞性肺疾病患者中以老年人群较为多见，与老年人体质状况较差、基础疾病较多密切相关[3-4]。年龄等因素也导致慢性阻塞性肺疾病患者中有很大比例同时合并肺部感染，这不仅降低了患者的生活质量，也给患者疾病的治疗增加了难度[5-6]。当慢性阻塞性肺疾病患者合并肺部感染时，患者的相关临床症状会加重，主要表现为患者气道分泌物增多、咳嗽程度加剧、呼吸困难、喘憋等。……